A-Alpha Bio is building a high-resolution model of biology by measuring protein interactions.

A-Alpha leverages its platform technology AlphaSeq to generate high-quality protein interaction data at scale, enabling the discovery of better drugs faster.
-
Industry
-
Milestones
- Lux investment: 2021
-
Founders
- David Younger
- Randolph Lopez
LUX Partners
-
Latest Tweets
- A-Alpha Bio has been selected as a finalist for the annual @geekwire Awards Health Innovation of the Year! It's a f… https://t.co/FAqXQjQqJq
- We are very excited to announce our collaboration with @Livermore_Lab to accelerate antibody discovery for emergin… https://t.co/C5ldVWhIbY
- As we prepare for a virtual company-wide retreat tomorrow, we can't help but reminisce on previous in-person team e… https://t.co/absa4jJjAW